Biotech

Bio & Pharma ABL Bio lands $2.8 billion license-out deal with GSK

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Mergers & Acquisitions CHA Biotech seeks to resume healthcare unit IPO after affiliates’ merger

CHA Biotech Co., South Korea’s leading stem cell therapeutics developer, plans to resume an initial public offering of CHA Healthcare Co., a m...

Artificial intelligence LG, SNU team up to develop AI modeling for protein structure predictions

LG AI Research Institute, the artificial intelligence think-tank of LG Group, South Korea’s fourth-biggest conglomerate, on Thursday signed a ...

Bio & Pharma Partners Investment, GordonMD eye $150 mn biotech fund launch

South Korean venture capital firm Partners Investment said on Thursday it will raise up to 215.5 billion won ($150 million) in a biotech fund jointl...

Business & Politics Latvian President Rinkēvičs seeks closer ties with S.Korea in bio, defense

Latvian President Edgars Rinkēvičs, who is on a four-day working trip to South Korea, said on Friday he hopes for deeper cooperation between the two...

Bio & Pharma SK Bioscience sells stake in US vaccine developer Novavax

SK Bioscience Co., a drug-making arm of South Korea's No. 2 conglomerate SK Group, has sold a stake in Nasdaq-listed vaccine developer Novavax Inc. ...

Korean stock market Biotech stocks, foreigners’ top pick in Korea amid panic selling

Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...

Bio & Pharma Samsung to invest $52 mn in US biotech VC Flagship Pioneering

Samsung C&T Corp., its bio units Samsung Biologics Co. and Samsung Bioepis Co. and Samsung Venture Investment Corp. have committed a combined 72...

Bio & Pharma Samsung’s biotech duo on a roll with $1.1 bn CMO order

Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...

Rights offerings Dim outlook for Korean biotech firms’ rights offerings

South Korea’s bio and tech-heavy Kosdaq-listed Shaperon Inc. raised 12.7 billion won ($9.2 million) from its latest rights offering, selling o...

Bio & Pharma Korean biotech Bertis to join BIO 2024 for global reach

South Korean biotech Bertis Inc. will deliver presentations at the BIO International Convention, one of the world’s largest bio and healthcare...

Bio & Pharma Investors dump Korean biotech HLB stocks on FDA rejection

HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...

IPOs Korean biotech Xcell Therapeutics eyes June IPO

South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...

Bio & Pharma Samsung Life Science invests in US biotech firm Latus Bio

Samsung Life Science Fund, managed by Samsung Group’s venture investment arm, has invested in US biotechnology firm Latus Bio Inc. during the ...

Bio & Pharma Samsung Biologics signs ADC CDO deal with LegoChem Bio

Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...

Leadership & Management Samsung’s Lee to spur M&As, new growth with ‘lost decade’ behind him

Cleared of wrongdoing charges that shackled his leadership for years, Samsung Group leader Jay Y. Lee now will actively seek mergers and acquisition...

Mergers & Acquisitions Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

Bio & Pharma Samsung eyes biotech investments via Flagship Pioneering

Samsung C&T Corp., Samsung Biologics Co. and Samsung Bioepis Co. will ramp up investments in US biotechnology startups in collaboration with Fla...

Bio & Pharma LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal

LegoChem Biosciences Inc. has signed a blockbuster $1.7 billion deal to license out its proprietary antibody drug conjugate (ADC) candidate to Jasse...

Upcoming IPOs Peter Thiel-backed D&D Pharmatech gets preliminary nod for IPO

South Korean clinical-stage biotech D&D Pharmatech Inc. has won approval from the Korea Exchange’s preliminary review for listing on the j...

Bio & Pharma Samsung Biologics partners with Europe's largest VC

Samsung Biologics Co., the world's largest contract drug manufacturer, announced on Tuesday it has teamed up with global biotech venture capitalist ...

Bio & Pharma Proxy adviser ISS backs drug giant Celltrion's merger plan

South Korean drug giant Celltrion Group has received a positive recommendation from Institutional Shareholder Services (ISS), a global leading proxy...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Bio & Pharma Wellmarker Bio signs worth of $528 mn tech transfer deal

Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a Europ...

Bio & Pharma AriBio applies for Phase 3 clinical trials in China for oral dementia drug

South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...

Bio & Pharma GI Innovation seeks to license allergy therapy to Japan in 2023

South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...

Bio & Pharma S.Korea to bolster biotech R&D, benchmarking US' Boston

South Korea is poised to boost the biotech industry by accelerating research, education and business partnerships with the biopharmaceutical sector ...

Bio & Pharma BIO USA 2023 to draw S.Korean biotech leaders, startups

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

Bio & Pharma NKMax submits US subsidiary's securities report to SEC

The listing in the US of NKGen Biotech, the American subsidiary of South Korean developer of natural killer (NK) cell therapy NKMax Co., is coming i...